Tag Archive > Anthracycline

Eisai Expands in Israeli Market With Approval of Halaven

Hatfield, England (ots/PRNewswire) – Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from the […]

Continue reading

, , , , , , , , , , , , , , , , , , ,

New Breast Cancer Treatment Available in France

Hatfield, England (ots/PRNewswire) – Reimbursement granted for Halaven(R) (eribulin) for women with locally advanced or metastatic breast cancer Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has today received reimbursement approval from the French health authorities. Prior […]

Continue reading

, , , , , , , , , , , , , , , , , , ,

German Federal Regulator Confirms Additional Benefit of eribulin for Metastatic or Locally Advanced Breast Cancer

Frankfurt And Hatfield, England (ots/PRNewswire) – ? The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, announced that it considers the use of Halaven(R) (eribulin) to have additional benefit versus comparative treatments, defined by the G-BA for women who have already had extensive prior treatment of metastatic […]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival

London (ots/PRNewswire) – – Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from a recently completed Phase III study with E7389 (generic name: eribulin mesylate, “eribulin”), discovered and developed by the Company, […]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Avastin Plus Commonly Used Chemotherapies Improves the Time Breast Cancer Patients Live Without Their Disease Getting Worse

Basel, Switzerland (ots/PRNewswire) – – RIBBON-1 Study Confirms Benefit of Avastin in Treating HER2-Negative Breast Cancer – For Non-US, Non-UK and Non-Austrian Media Results from the phase III RIBBON-1 study presented today at ASCO showed that patients with advanced HER2-negative breast cancer who were treated with Avastin(R) (bevacizumab) plus the most commonly used chemotherapies lived […]

Continue reading

, , , , , , , , , , , , , , , , , , ,